Skip to main content

Nicotinamide Riboside for Mild Cognitive Impairment

Recruiting

This Phase I/II study will test the supplement nicotinamide riboside, also known as Niogen, as a potential treatment for age-related memory loss.

Minimum Age Maximum Age Gender Healthy Volunteers
60 Years 90 Years All No
December 1, 2018
March 2022
58

  • Cognitive function scores consistent with amnestic mild cognitive impairment
  • Mini-Mental State Examination score of 24 or more 

  • Evidence of abnormal kidney, liver, thyroid, or adrenal function; estimated glomerular filtration rate must be greater than 60 ml/min/1.73 m2
  • Significant abnormal blood chemistry values
  • Major psychiatric disorder (e.g., schizophrenia, bipolar disorder, or major depression within past 2 years)
  • Neurological or autoimmune conditions affecting cognition (e.g., Parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct)
  • Concussion within last 2 years and 3 lifetime concussions
  • Systemic medical illnesses (e.g., cardiovascular disease, cancer, kidney failure)
  • Substance abuse or dependence
  • Current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines)
  • Inability to undergo magnetic resonance imaging, including claustrophobia, metal implants, and pacemaker
  • Smoking (including marijuana) within the past 3 months

Nicotinamide riboside is a form of vitamin B3. Participants will be randomly assigned to take a placebo or study supplement (two capsules twice daily) for 3 months. Researchers will track changes in cognitive function, including memory and attention, as well as measures of brain blood flow.

Name City State Zip Status Primary Contact
Neurovascular Aging Laboratory
Newark Delaware 19713 Recruiting Joshua Hobson, MS
302-831-8137
chs-novalab@udel.edu

University of Delaware

  • National Institute on Aging (NIA)

Name Role Affiliation
Christopher R. Martens, Ph.D. Principal Investigator University of Delaware

NCT03482167

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment